TECTONIC THERAPEUTIC, INC. Proceeds from Sale of Buildings
TECTONIC THERAPEUTIC, INC. (TECX) reported Proceeds from Sale of Buildings of $83.74 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfBuildings · last filed 2024-03-14
- TECTONIC THERAPEUTIC, INC. proceeds from sale of buildings for the quarter ending 2023-12-31 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from sale of buildings for the quarter ending 2023-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from sale of buildings for the quarter ending 2022-12-31 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from sale of buildings for the quarter ending 2022-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from sale of buildings for fiscal 2023 was $83.74M.
- TECTONIC THERAPEUTIC, INC. proceeds from sale of buildings for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale of Buildings 3 month | Proceeds from Sale of Buildings 6 month | Proceeds from Sale of Buildings 9 month | Proceeds from Sale of Buildings 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $83.74M 10-K · filed 2024-03-14 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $83.74M 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $83.74M 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |